Annual Reports

FY19 Annual Report

During the 2019 financial year, we have been focused on creating a company that is competitive, resilient and innovative, allowing us to successfully navigate in a complex and constantly changing environment. One of Dimerix' greatest capabilities is the therapeutic science; we are a very small team but have attracted world-class scientists, clinical researchers and medical professionals. To this end, the 2019 financial year has been extremely busy making solid progress in addressing the near-term strategic priorities that we believe will enable us to achieve our objective of delivering on DMX-200 in two different indications, as well as diversifying risk through broadening our product portfolio.

Download Opens in new window

Join the Dimerix mailing list to receive the latest company news.

Join now